MedTrace Logo

Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC

NCT07523789 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2026-04-13

No results posted yet for this study

Summary

This study is an observational study that retrospectively collects data of triple-negative breast cancer patients who received neoadjuvant therapy. It compares the bpCR rate, apCR rate, and tpCR rate of patients treated with chemotherapy or immunotherapy, in order to analyze the efficacy and influencing factors of chemotherapy and immunotherapy in neoadjuvant therapy for triple-negative breast cancer.

Conditions

  • TNBC, Triple Negative Breast Cancer

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Jue Wang · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-02-01
Completion
2027-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07523789 on ClinicalTrials.gov